

Abstract

The invention relates to G-protein coupled receptor EDG6 and its fragments, variants and mutations as well as its use. Fields of application of the invention are molecular biology, pharmacy and medicine.

The invention was based on the task of isolating and identifying a further member of the EDG receptor family and making it useful for a medicinal application.

The new human EDG6 receptor entails 384 amino-acids of Sequence 1 with seven transmembrane domains. The receptor possesses a possible N-terminal glycosylation point, three possible palmitoylation points positioned 12 to 15 amino-acids C-terminally from the seventh transmembrane domain as well as four possible C-terminal proteinkinase C-phosphorylation points.

The invention also relates to the use of the EDG6 receptors as well as its fragments, variants and mutations and, if applicable, its binding partners for therapeutic methods and treatments.